Precigen achieves significant clinical progress for ultracar-t® and adenoverse™ therapies

Germantown, md., nov. 4, 2021 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, announced a topline summary of the presentations planned for today's 2021 r&d day virtual event, which begins at 11:00 am et.
PGEN Ratings Summary
PGEN Quant Ranking